Publications by authors named "M A Almekhlafi"
Background And Purpose: Successful and complete reperfusion should be the aim of every endovascular thrombectomy (EVT) procedure. However, the effect of time delays on successful reperfusion in late window stroke patients presenting 6-to-24 h from onset has not been investigated.
Materials And Methods: We pooled individual patient-level data from seven trials and registries for anterior circulation stroke patients treated with EVT between 6 and 24 h from onset.
Article Synopsis
- Non-stenotic carotid plaques, identified as having less than 50% stenosis, are considered a potential factor in ischemic strokes, particularly in patients with low-risk neurological events.
- The study analyzed data from 334 patients who experienced minor neurological symptoms and underwent CT angiography and MRI, finding that nearly 46% had these non-stenotic plaques, with a notable prevalence among those showing DWI-positive ischemia.
- The results indicated that non-stenotic plaques are more common on the side of DWI-positive lesions, suggesting a significant association between these plaques and the risk of ischemic events, as patients with non-stenotic plaques had a 40% higher risk for DWI-positive ischemia.
Background: About 25% of patients with acute ischemic stroke have lacunar infarct on follow-up imaging. In this secondary analysis from the AcT (Alteplase Compared With Tenecteplase) trial, we assessed if there is variation in safety or efficacy of intravenous thrombolysis by infarct type in patients with no visible occlusion. We also determined if this effect differed between tenecteplase and alteplase.
View Article and Find Full Text PDFBackground: In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide's effect on infarct volume.
Methods: ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo.
Background: The Edmonton-based mobile stroke unit (MSU), which transports patients to the University of Alberta Hospital (UAH), enrolled patients in the Intravenous Tenecteplase Compared with Alteplase for Acute Ischemic Stroke (AcT) trial. We examined the feasibility of trial enrollment in MSU, its impact on acute stroke workflow metrics and functional outcomes at 90-120 days.
Methods: In this post hoc analysis, patients were divided into three groups based on enrollment site: MSU ( = 43), UAH ( = 273) and non-UAH ( = 1261).